BRUSSELS, BELGIUM -- (MARKET WIRE) -- January 25, 2007 -- UCB today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants marketing authorisation for Xyrem® (sodium oxybate) in the treatment of narcolepsy with cataplexy in adult patients. The European Commission is expected to issue a decision within approximately six weeks.
